Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 394

Sort by

Sort Order Select

Journal Articles

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Blood (2024) 144 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2024-209692

Published: 2024

Journal Articles

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Blood (2024) 144 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2024-208727

Published: 2024

Journal Articles

Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents

Malte Knöll, Rashmi Priyadharshini Dheenadayalan, Deyan Y. Yosifov, Jialei Qi, Christof Schneider, Felix Seyfried, Lueder Hinrich Meyer, Paula Cramer, Julia Von Tresckow, Michael Hallek, Barbara F. Eichhorst, Eugen Tausch, Stephan Stilgenbauer, Billy Jebaraj

Blood (2024) 144 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2024-204910

Published: 2024

Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2024-203673

Published: 2024

Journal Articles

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Blood (2024) 144 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2024-200848

Published: 2024

Journal Articles

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Blood (2024) 144 (Supplement 1): 4626.

https://doi.org/10.1182/blood-2024-204852

Published: 2024

Journal Articles

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Blood (2024) 144 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2024-200903

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour

Blood (2024) 144 (Supplement 1): 885.

https://doi.org/10.1182/blood-2024-199116

Published: 2024

Journal Articles

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2024) 144 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2024-198917

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood (2024) 144 (18): 1924–1935.

https://doi.org/10.1182/blood.2024024631

Published: 2024

Includes: Supplemental data

Journal Articles

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood (2024) 144 (5): 510–524.

https://doi.org/10.1182/blood.2023021990

Published: 2024

Includes: Supplemental data

Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Blood (2024) 144 (3): 272–282.

https://doi.org/10.1182/blood.2023022730

Published: 2024

Includes: Supplemental data

Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood (2024) 143 (25): 2588–2598.

https://doi.org/10.1182/blood.2023022564

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Blood (2023) 142 (Supplement 1): 204.

https://doi.org/10.1182/blood-2023-188705

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer

Blood (2023) 142 (Supplement 1): 199.

https://doi.org/10.1182/blood-2023-180558

Published: 2023

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Journal Articles

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Blood (2023) 142 (Supplement 1): 6248.

https://doi.org/10.1182/blood-2023-179200

Published: 2023

NARROW

In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only